A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Concizumab (Primary) ; Turoctocog alfa
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms Explorer 5
- Sponsors Novo Nordisk
- 07 Sep 2018 Planned End Date changed from 15 Aug 2019 to 31 Mar 2020.
- 31 Aug 2018 Biomarkers information updated
- 10 May 2018 This trial has been completed in Germany (End date: 2018-04-10).